A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

Status
Active
Cancer Type
Breast Cancer
Trial Phase
Phase I
Phase II
Eligibility
18 and over, Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01446159
Protocol IDs
CD-ON-MEDI-573-1030 (primary)
Study Sponsor
MedImmune, Incorporated

Summary

This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-negative MBC. This study has 2 phases: a dose-evaluation phase (Phase 1b) and a randomization phase (Phase 2).

Treatment Sites in Georgia


Suburban Hematology-Oncology Associates - Duluth
3855 Pleasant Hill Road
Suite 480
Duluth, GA 30096
www.cancergwinnett.com

Study Coordinator:
Kathy Frank
(678) 533-1567

Doctors:

Christopher T. Hagenstad MD

Suburban Hematology-Oncology Associates - Snellville
1700 Tree Lane Road
Suite 490
Snellville, GA 30078
www.cancergwinnett.com

Study Coordinator:
Kathy Frank
(678) 533-1567

Doctors:

Allan Freedman MD
P. Ravi Sarma MD, FACP
Satvir Singh MD